Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor
Ayad K AliDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USABackground: The purpose of this study was to examine the postmarketing safety profile of aliskiren hemifumarate, a first-in-class direct renin inhibitor.Methods: The US Adverse...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2011-08-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | http://www.dovepress.com/pharmacovigilance-analysis-of-adverse-event-reports-for-aliskiren-hemi-a8041 |
| _version_ | 1818732902887718912 |
|---|---|
| author | Ali AK |
| author_facet | Ali AK |
| author_sort | Ali AK |
| collection | DOAJ |
| description | Ayad K AliDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USABackground: The purpose of this study was to examine the postmarketing safety profile of aliskiren hemifumarate, a first-in-class direct renin inhibitor.Methods: The US Adverse Event Reporting System (AERS) was utilized to conduct a retrospective pharmacovigilance analysis by applying the Multi-item Gamma Poisson Shrinker data mining algorithm to calculate empiric Bayes geometric mean (EBGM) values of aliskiren-related adverse event reports. Reports received from January 2007 through December 2008 are included in this analysis.Results: In total, 1592 reports for aliskiren are identified in the AERS. Aliskiren was associated with reports of angioedema (EBGM 3.9, 95% confidence interval [CI] 3.2–4.7) and renal dysfunction (EBGM 3.4, 95% CI 2.6–4.5). Reports of hyperkalemia, dry cough, and diarrhea were also linked to aliskiren (EBGM 7.4, 95% CI 3.4–13.0, EBGM 11.0, 95% CI 7.8–14.2, EBGM 4.3, 95% CI 3.2–5.8, respectively).Conclusion: Angioedema and renal dysfunction are potential adverse events associated with exposure to aliskiren. Patients with signs and symptoms of angioedema should stop aliskiren and seek urgent medical help. Aliskiren should not be used by patients with a risk of renal impairment. Additional studies are warranted to quantify further the risk of these events in patients with hypertension.Keywords: aliskiren, postmarketing safety surveillance, adverse event reporting system |
| first_indexed | 2024-12-17T23:40:57Z |
| format | Article |
| id | doaj.art-de54e087d6be4532aa991999dd520292 |
| institution | Directory Open Access Journal |
| issn | 1176-6336 1178-203X |
| language | English |
| last_indexed | 2024-12-17T23:40:57Z |
| publishDate | 2011-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-de54e087d6be4532aa991999dd5202922022-12-21T21:28:27ZengDove Medical PressTherapeutics and Clinical Risk Management1176-63361178-203X2011-08-012011default337344Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitorAli AKAyad K AliDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USABackground: The purpose of this study was to examine the postmarketing safety profile of aliskiren hemifumarate, a first-in-class direct renin inhibitor.Methods: The US Adverse Event Reporting System (AERS) was utilized to conduct a retrospective pharmacovigilance analysis by applying the Multi-item Gamma Poisson Shrinker data mining algorithm to calculate empiric Bayes geometric mean (EBGM) values of aliskiren-related adverse event reports. Reports received from January 2007 through December 2008 are included in this analysis.Results: In total, 1592 reports for aliskiren are identified in the AERS. Aliskiren was associated with reports of angioedema (EBGM 3.9, 95% confidence interval [CI] 3.2–4.7) and renal dysfunction (EBGM 3.4, 95% CI 2.6–4.5). Reports of hyperkalemia, dry cough, and diarrhea were also linked to aliskiren (EBGM 7.4, 95% CI 3.4–13.0, EBGM 11.0, 95% CI 7.8–14.2, EBGM 4.3, 95% CI 3.2–5.8, respectively).Conclusion: Angioedema and renal dysfunction are potential adverse events associated with exposure to aliskiren. Patients with signs and symptoms of angioedema should stop aliskiren and seek urgent medical help. Aliskiren should not be used by patients with a risk of renal impairment. Additional studies are warranted to quantify further the risk of these events in patients with hypertension.Keywords: aliskiren, postmarketing safety surveillance, adverse event reporting systemhttp://www.dovepress.com/pharmacovigilance-analysis-of-adverse-event-reports-for-aliskiren-hemi-a8041 |
| spellingShingle | Ali AK Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor Therapeutics and Clinical Risk Management |
| title | Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor |
| title_full | Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor |
| title_fullStr | Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor |
| title_full_unstemmed | Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor |
| title_short | Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor |
| title_sort | pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate a first in class direct renin inhibitor |
| url | http://www.dovepress.com/pharmacovigilance-analysis-of-adverse-event-reports-for-aliskiren-hemi-a8041 |
| work_keys_str_mv | AT aliak pharmacovigilanceanalysisofadverseeventreportsforaliskirenhemifumarateafirstinclassdirectrenininhibitor |